ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to...

Area of Science:

• Pharmacogenomics
• Clinical Pharmacology
• Molecular Biology

Background:

• Clopidogrel is a vital antiplatelet medication for preventing ischemic events post-acute coronary syndrome and stent implantation.
• Individual responses to clopidogrel vary due to genetic factors, notably single nucleotide polymorphisms (SNPs) like CYP2C19*2 and ABCB1 C3435T.
• The varying prevalence of these SNPs across different populations necessitates localized studies to guide treatment.

Purpose of the Study:

• To determine the allele frequencies of CYP2C19*2 and ABCB1 C3435T polymorphisms in Palestinian and Turkish populations.
• To provide crucial data for optimizing clopidogrel therapy in these specific ethnic groups.
• To highlight the importance of pharmacogenetic testing for personalized antiplatelet treatment.

Main Methods:

• Genotyping of 100 unrelated Palestinian and 100 unrelated Turkish subjects.
• Utilized the amplification refractory mutation system (ARMS) for SNP analysis.
• Quantified allele frequencies and confidence intervals for CYP2C19*2 and ABCB1 C3435T.

Main Results:

• ABCB1 C3435T allele frequency was 0.46 in Palestinians and 0.535 in Turks.
• CYP2C19*2 allele frequency was 0.095 in Palestinians and 0.135 in Turks.
• Significant differences in allele frequencies were observed between the two populations.

Conclusions:

• The study establishes baseline prevalence data for key clopidogrel-related SNPs in Palestinian and Turkish populations.
• Findings underscore the need for population-specific pharmacogenetic information to enhance clopidogrel's safety and efficacy.
• Genetically guided individualized treatment strategies are crucial for improving therapeutic outcomes with clopidogrel.